Clinical trial · Interventional
Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection
CLASSICAL ANTAGONIST PROTOCOL IN COMPARISON WITH AGONIST STOP PROTOCOL IN Polycystic Ovary Symdrome WOMEN UNDERGOING Intra-cytoplasmic Injection TRIAL: a Randomized Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Stein and Leventhal were the first to recognize an association between the presence of polycystic ovaries and signs of hirsutism and amenorrhea (eg,oligomenorrhea, obesity), After women diagnosed with Stein-Leventhal syndrome underwent successful wedge resection of the ovaries, their menstrual cycles became regular, and they were able to conceive. As a consequence, a primary ovarian defect was thought to be the main culprit, and the disorder came to be known as polycystic ovarian disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cetrorelix | Drug | — | UNRESOLVED |
| Leuprolide Acetate | Drug | Leuprolide | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Study group
- description
- the antagonist protocol group" where they will do intra-cytoplasmic injection using classical antagonist protocol
- interventionNames
- Drug: Cetrorelix
- type
- ACTIVE_COMPARATOR
- label
- control group
- description
- "agonist stop/antagonist protocol group" where they will receive mid luteal agonist in the preceding intra-cytoplasmic injection cycle before starting classical antagonist protocol
- interventionNames
- Drug: Cetrorelix
- Drug: Leuprolide Acetate
Primary outcomes (1)
- measure
- The difference in clinical pregnancy rate in both groups
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: 1. Women under 35 years with polycystic ovary syndrome criteria 2. Normal male semen parameters 3. Normal tubes either by hysterosalpingography \&/or laparoscopy 4. Free from other endocrine abnormalities Exclusion Criteria: 1. NON polycystic ovary syndrome Criteria 2. More than 35 years 3. Abnormal semen parameters 4. Pathological tube\& pelvic factor 5. Other endocrine disorders
References
Publications (0)
Data not yet available